http://www.imim.cat/noticies Programa de recerca: Neuropsicofarmacologia http://www.imim.cat/noticies/view.php?ID=690 <p>Phase 1/2 of the clinical trial shows that the administration of the AEF0217 molecule developed by the biotech Aelis Farma, is safe and can improve key skills such as communication, social interactions and daily living for people with Down syndrome</p> <p>These results reinforce the start of the phase 2 clinical trial, through an international multicenter study with people with Down syndrome, focused on the dose necessary to achieve the treatment goal</p> 17/12/2024